Promore – Reports and prospectus

Interim Reports (Promore) November 29, 2022 Delårsrapport januari – september 2022	Report (pdf)
Interim Reports (Promore) November 29, 2022 Interim report January – September 2022	Report (pdf)
Interim Reports (Promore) August 30, 2022 Promore Pharma Delårsrapport januari – juni 2022	Report (pdf)
Interim Reports (Promore) August 30, 2022 Promore Pharma Interim report January – June 2022	Report (pdf)
Interim Reports (Promore) May 17, 2022 Promore Pharma — delårsrapport januari-mars 2022	Report (pdf)
Interim Reports (Promore) May 17, 2022 Promore Pharma — interim report January-March 2022	Report (pdf)
Annual Reports (Promore) April 26, 2022 Årsredovisning 2021	Report (pdf)
Annual Reports (Promore) April 26, 2022 Annual Report 2021	Report (pdf)
Interim Reports (Promore) February 16, 2022 Delårsrapport januari – December 2021	Report (pdf)
Interim Reports (Promore) February 16, 2022 Interim report January – December 2021	Report (pdf)

MESSAGE FROM THE CEO

Read what our CEO has to say about our business.

Read the CEO message

BUSINESS MODEL

The RespiraSense™ business model consists of several components that together create a complete delivery that generates attractive gross margins and recurring revenues.

Learn more about the business model

VISION

To avoid preventable respiratory failure events by transforming the standard of care in patient monitoring.

MISSION

To become the de facto standard-of-care for monitoring respiratory compromised patients in Europe and the US.